Erlotinib is a targeted therapy drug primarily used to treat certain types of cancer by inhibiting cancer cell growth. It belongs to a class of medications known as tyrosine kinase inhibitors (TKIs) and specifically targets the epidermal growth factor receptor (EGFR).

1. Non-Small Cell Lung Cancer (NSCLC):

   • For advanced or metastatic NSCLC with EGFR mutations.
   • Frequently utilized in situations where chemotherapy isn't compelling.

2. Pancreatic Cancer:

   • Utilized in blend with gemcitabine for cutting edge pancreatic malignant growth.

• Erlotinib blocks the EGFR tyrosine kinase, a protein involved in cell signaling pathways that regulate cell growth and division.
• By inhibiting EGFR, Erlotinib prevents the growth and spread of cancer cells that rely on this pathway.

• Dosage: Typically taken as an oral tablet once daily, at least one hour before or two hours after meals.
• Duration: The length of treatment depends on the type and stage of cancer and how well the patient responds to the medication.

• Rash or acne-like skin reactions
• Diarrhea
• Fatigue
• Loss of appetite
• Nausea and vomiting
• Dry skin

• Severe lung problems (interstitial lung disease)
• Liver or kidney dysfunction
• Eye irritation or damage

• Not suitable for pregnant or breastfeeding women.
• Avoid smoking, as it reduces the effectiveness of the drug.
• Regular monitoring of liver, kidney function, and lung health is necessary.